| CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response D Biasci, M Smoragiewicz, CM Connell, Z Wang, Y Gao, ... Proceedings of the National Academy of Sciences 117 (46), 28960-28970, 2020 | 188 | 2020 |
| Imaging breast cancer using hyperpolarized carbon-13 MRI FA Gallagher, R Woitek, MA McLean, AB Gill, R Manzano Garcia, ... Proceedings of the National Academy of Sciences 117 (4), 2092-2098, 2020 | 188 | 2020 |
| Quantifying normal human brain metabolism using hyperpolarized [1–13C] pyruvate and magnetic resonance imaging JT Grist, MA McLean, F Riemer, RF Schulte, SS Deen, F Zaccagna, ... Neuroimage 189, 171-179, 2019 | 180 | 2019 |
| Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study FM Walter, K Mills, SC Mendonça, GA Abel, B Basu, N Carroll, S Ballard, ... The lancet Gastroenterology & hepatology 1 (4), 298-306, 2016 | 168 | 2016 |
| Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer HM Kocher, B Basu, FEM Froeling, D Sarker, S Slater, D Carlin, ... Nature communications 11 (1), 4841, 2020 | 161 | 2020 |
| First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014 B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ... Clinical cancer research 21 (15), 3412-3419, 2015 | 128 | 2015 |
| Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin B Basu, B Sirohi, P Corrie Endocrine-Related Cancer 17 (1), R75-R90, 2010 | 118 | 2010 |
| A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma N Cook, B Basu, DM Smith, A Gopinathan, J Evans, WP Steward, ... British journal of cancer 118 (6), 793-801, 2018 | 115 | 2018 |
| MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial D Sarker, R Plummer, T Meyer, MH Sodergren, B Basu, CE Chee, ... Clinical cancer research 26 (15), 3936-3946, 2020 | 107 | 2020 |
| First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. JS De Bono, LA Mina, M Gonzalez, NJ Curtin, E Wang, JW Henshaw, ... Journal of Clinical Oncology 31 (15_suppl), 2580-2580, 2013 | 107 | 2013 |
| Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers TA Yap, R Kristeleit, V Michalarea, SJ Pettitt, JSJ Lim, S Carreira, D Roda, ... Cancer discovery 10 (10), 1528-1543, 2020 | 99 | 2020 |
| Combining antiangiogenics to overcome resistance: rationale and clinical experience V Moreno Garcia, B Basu, LR Molife, SB Kaye Clinical Cancer Research 18 (14), 3750-3761, 2012 | 83 | 2012 |
| Targeting the DNA damage response in oncology: past, present and future perspectives B Basu, TA Yap, LR Molife, JS De Bono Current opinion in oncology 24 (3), 316-324, 2012 | 78 | 2012 |
| A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer AM Oza, UA Matulonis, A Alvarez Secord, J Nemunaitis, LD Roman, ... Clinical Cancer Research 26 (5), 1009-1016, 2020 | 77 | 2020 |
| LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. C Gomez-Roca, E Yanez, SA Im, E Castanon Alvarez, H Senellart, ... Journal of Clinical Oncology 39 (3_suppl), 94-94, 2021 | 67 | 2021 |
| Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial M Alunni-Fabbroni, K Rönsch, T Huber, CC Cyran, M Seidensticker, ... Journal of translational medicine 17, 1-15, 2019 | 61 | 2019 |
| Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer A Hashimoto, D Sarker, V Reebye, S Jarvis, MH Sodergren, A Kossenkov, ... Clinical Cancer Research 27 (21), 5961-5978, 2021 | 59 | 2021 |
| Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: A single-centre, open-label, phase 1 … C Guo, M Chénard-Poirier, D Roda, M de Miguel, SJ Harris, IM Candilejo, ... The Lancet Oncology 21 (11), 1478-1488, 2020 | 55 | 2020 |
| Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience E Ghorani, HH Wong, C Hewitt, J Calder, P Corrie, B Basu Oncology 89 (5), 281-287, 2015 | 55 | 2015 |
| Assessing the impact of COVID-19 on liver cancer management (CERO-19) S Muñoz-Martínez, V Sapena, A Forner, JC Nault, G Sapisochin, ... JHEP reports 3 (3), 100260, 2021 | 53 | 2021 |
